Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance (PILATE)
Primary Purpose
Diarrhea Predominant Irritable Bowel Syndrome
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Lactibiane Tolerance
Sponsored by
About this trial
This is an interventional treatment trial for Diarrhea Predominant Irritable Bowel Syndrome
Eligibility Criteria
Inclusion Criteria:
- Age from 18 to 75;
- With symptoms of IBS with predominant diarrhea according to the Rome III criteria;
- For women of childbearing age: effective contraception and agreement to keep it throughout the study;
- General and mental health compatible with participation in the study and to be followed as an outpatient in the opinion of the investigator: no clinically significant and relevant abnormality according to medical history and physical examination;
- Agreeing to maintain their lifestyle during the study (same eating habits and physical activity);
- Able and willing to participate in research in accordance with the protocol procedures particularly regarding consumption of the product under consideration and having signed an informed consent form dated;
- Belonging to a social security scheme;
- Willing to be included in the file of volunteers participating in biomedical research.
Exclusion Criteria:
- Having a history of hypersensitivity to any of the ingredients of the product under consideration;
- Having a history of hypersensitivity to fluorescein and / or red carmine (E120 food coloring);
- With immunodeficiency or with a severe or progressive disease (cardiac, pulmonary, hepatic, renal, hematologic, neoplastic, or infectious);
- With acute or severe chronic disease (chronic alcoholism, drug addiction) found incompatible with participation in the study by the investigator;
- Suffering from a metabolic disorder or a chronic inflammatory digestive disease affecting the intestinal transit or absorption of nutrients such as diabetes, hyperthyroidism, celiac disease or Crohn's disease;
- Having a medical history or current condition that, according to the investigator, may interfere with the results of the study or expose the subject to additional risk;
- Currently under medication or food supplement treatment, according to the investigator, may interfere with the results of the study or stopped within too short before inclusion in V1 (less than a month for antibiotics, pre and probiotics, less than 14 days for antidiarrheal, steroidal anti-inflammatories, NSAIDs, aspirin, antihistamines and drugs. treatment with maximum 2 concomitant psychotropic can be tolerated only if it exists for more than 3 months before inclusion);
- Having a lifestyle incompatible with the study by the investigator;
- Woman during pregnancy or breastfeeding or planning to become pregnant within 2 months;
- Planning to travel and hold during the study period or impossible to contact in case of emergency;
- Having a psychological or linguistic inability to understand and sign the informed consent;
- Participating in another clinical trial or exclusion period of a previous clinical trial;
- Having received over the past 12 months, no more than 4,500 euros in payment for participation in clinical trials;
- Under legal protection (guardianship, trusteeship) or deprived of his rights under the administrative or judicial decision.
Sites / Locations
- CHU-Hôtel-Dieu, Service d'Hépato-gastro-entérologie
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Single arm
Arm Description
Supplementation with Lactibiane Tolerance
Outcomes
Primary Outcome Measures
Change from baseline of intestinal permeability
Evolution between V1 and V2 of intestinal permeability evaluated by the lactulose-mannitol test according to the slope of urinary excretion of ingested lactulose percentage (calculated by linear regression) during the period representing the passage into the small intestine (2 to 4 hours after ingestion of lactulose-mannitol mixture).
Secondary Outcome Measures
Change from baseline of intestinal permeability - secondary 1
Evolution of slope percentages urinary excretion (UE) of ingested mannitol ([M]) (calculated by linear regression) during the period representing the Passage Into the Small Intestine (PISI) (2 to 4 hours (h) after ingestion of [L]-[M] mixture)
Change from baseline of intestinal permeability - secondary 2
Evolution of the ratio between the slopes of the UE percentages of lactulose ([L]) and [M] ingested during the PISI (2 to 4h after ingestion of lactulose-mannitol mixture)
Change from baseline of intestinal permeability - secondary 3
Evolution of the percentage of UE of [L] ingested on the excretion of ingested [M] during the period representing the PISI (2 to 4h after ingestion)
Change from baseline of intestinal permeability - secondary 4
Evolution of the UE percentage of [L] ingested on the UE of ingested [M] each lap of the period representing the PISI
Change from baseline of intestinal permeability - secondary 5
Evolution of he percent UE of [L] ingested on the UE of ingested [M] during the period representing the passage in the colon (between 4 and 5h after ingestion)
Change from baseline of intestinal permeability - secondary 6
Evolution of the percent UE of [L] ingested on the UE of ingested [M] during the period of 5h after ingestion
Change from baseline of intestinal permeability - secondary 7
Evolution of the UE percentage of [L] ingested on the UE of ingested [M] during the transition period representative of the stomach to the small intestine (between 0 and 2h after
Change from baseline of intestinal permeability - secondary 8
Evolution of the Percentage of UE of [L] and [M] ingested during the period representing the PISI (2 to 4h after ingestion)
Change from baseline of intestinal permeability - secondary 9
Evolution of the Percentage of UE of [L] and [M] ingested during a period of 5h after ingestion
Change from baseline of intestinal permeability - secondary 10
Evolution of the Percentage of UE of [L] and [M] ingested each 5h lap
Change from the baseline of the inflammatory status - secondary 11
Evolution between V1 and V2 of inflammatory status by fecal calprotectin
Change from the baseline of the symptomatology - secondary 12
Time to onset of the first colored red stool after taking carmine red capsules (minutes)
Change from the baseline of the symptomatology - secondary 13
Average intensity of 7 days of the worst abdominal pain on Likert scale (11 points)
Change from the baseline of the symptomatology - secondary 14
Medium intensity of 7 days of abdominal discomfort on Likert scale (11 points)
Change from the baseline of the symptomatology - secondary 15
Stool consistency average of 7 days after Bristol Stool Scale (BSS)
Change from the baseline of the symptomatology - secondary 16
Mean daily stool frequency of 7 days after BSS quiz
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02728063
Brief Title
Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
Acronym
PILATE
Official Title
Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
May 11, 2016 (Actual)
Primary Completion Date
April 11, 2018 (Actual)
Study Completion Date
April 11, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PiLeJe
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objective of the study is to evaluate the effect on intestinal permeability of a supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from irritable bowel syndrome (IBS) with diarrhea predominance.
Secondary objectives of the study are to evaluate the effects of supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from IBS with diarrhea predominance on intestinal permeability, inflammation of the digestive tract, symptoms and comfort.
Single-center study in single open arms: 30 volunteer adults suffering from Irritable Bowel Syndrome (IBS) with diarrhea predominance and matching the criteria of inclusion and non-inclusion listed below.
Detailed Description
single-center pilot study in single open arm:
2 to 6 weeks before enrollment: a screening visit (visit 0 [V0]) is carried out for verification of eligibility. time between V0 and V1 is a wash-out period with a duration decided by the physician (max 8 weeks).
The experimental phase is composed of 2 visits (Visit 1 [V1] and Visit 2 [V2]) separated by 28 days (± 2 days) : from V1 to V2 patients are taking the product Lactibiane Tolérance®.
V1 and V2 each include collection of stools, a blood sample, questionnaires on abdominal symptoms and quality of life, dynamic test of absorption of lactulose / mannitol to evaluate the intestinal permeability, recto-sigmoidoscopy with confocal endomicroscopy for in-vivo study of fluorescein leakage in the lamina propria and biopsies for ex-vivo measurements.
"carmine red" test for the evaluation of intestinal transit speed is carried out the week before V1 and V2 (at least 72 hours before the visit). Questionnaires on abdominal symptoms as well as the frequency and consistency of stools are filled during the 7 days before V1 and V2 before.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea Predominant Irritable Bowel Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Single arm
Arm Type
Experimental
Arm Description
Supplementation with Lactibiane Tolerance
Intervention Type
Dietary Supplement
Intervention Name(s)
Lactibiane Tolerance
Intervention Description
probiotics
Primary Outcome Measure Information:
Title
Change from baseline of intestinal permeability
Description
Evolution between V1 and V2 of intestinal permeability evaluated by the lactulose-mannitol test according to the slope of urinary excretion of ingested lactulose percentage (calculated by linear regression) during the period representing the passage into the small intestine (2 to 4 hours after ingestion of lactulose-mannitol mixture).
Time Frame
at day 0 and day 28
Secondary Outcome Measure Information:
Title
Change from baseline of intestinal permeability - secondary 1
Description
Evolution of slope percentages urinary excretion (UE) of ingested mannitol ([M]) (calculated by linear regression) during the period representing the Passage Into the Small Intestine (PISI) (2 to 4 hours (h) after ingestion of [L]-[M] mixture)
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 2
Description
Evolution of the ratio between the slopes of the UE percentages of lactulose ([L]) and [M] ingested during the PISI (2 to 4h after ingestion of lactulose-mannitol mixture)
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 3
Description
Evolution of the percentage of UE of [L] ingested on the excretion of ingested [M] during the period representing the PISI (2 to 4h after ingestion)
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 4
Description
Evolution of the UE percentage of [L] ingested on the UE of ingested [M] each lap of the period representing the PISI
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 5
Description
Evolution of he percent UE of [L] ingested on the UE of ingested [M] during the period representing the passage in the colon (between 4 and 5h after ingestion)
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 6
Description
Evolution of the percent UE of [L] ingested on the UE of ingested [M] during the period of 5h after ingestion
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 7
Description
Evolution of the UE percentage of [L] ingested on the UE of ingested [M] during the transition period representative of the stomach to the small intestine (between 0 and 2h after
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 8
Description
Evolution of the Percentage of UE of [L] and [M] ingested during the period representing the PISI (2 to 4h after ingestion)
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 9
Description
Evolution of the Percentage of UE of [L] and [M] ingested during a period of 5h after ingestion
Time Frame
at day 0 and day 28
Title
Change from baseline of intestinal permeability - secondary 10
Description
Evolution of the Percentage of UE of [L] and [M] ingested each 5h lap
Time Frame
at day 0 and day 28
Title
Change from the baseline of the inflammatory status - secondary 11
Description
Evolution between V1 and V2 of inflammatory status by fecal calprotectin
Time Frame
at day 0 and day 28
Title
Change from the baseline of the symptomatology - secondary 12
Description
Time to onset of the first colored red stool after taking carmine red capsules (minutes)
Time Frame
at week 0 and week 4
Title
Change from the baseline of the symptomatology - secondary 13
Description
Average intensity of 7 days of the worst abdominal pain on Likert scale (11 points)
Time Frame
at week 0 and week 4
Title
Change from the baseline of the symptomatology - secondary 14
Description
Medium intensity of 7 days of abdominal discomfort on Likert scale (11 points)
Time Frame
at week 0 and week 4
Title
Change from the baseline of the symptomatology - secondary 15
Description
Stool consistency average of 7 days after Bristol Stool Scale (BSS)
Time Frame
at week 0 and week 4
Title
Change from the baseline of the symptomatology - secondary 16
Description
Mean daily stool frequency of 7 days after BSS quiz
Time Frame
at week 0 and week 4
Other Pre-specified Outcome Measures:
Title
Parameters measured ex vivo from colonic biopsies placed in Ussing chamber : change from baseline of paracellular permeability
Description
Evolution of the slope ( determined by linear regression ) and area under the curve of evolution of the concentration of sulfonic acid fluorescence (measured in the basolateral chamber ) over time (measured every 30 min for 3 hours )
Time Frame
at day 0 and day 28
Title
Parameters measured ex vivo from colonic biopsies placed in Ussing : change from baseline of transcellular permeability
Description
Evolution of the slope ( calculated by linear regression) and area under the curve of evolution of the concentration of Horse Radish Peroxidase (HRP) (measured in the basolateral chamber ) over time (measured every 30 minutes between 1 and 3 hours) .
Time Frame
at day 0 and day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age from 18 to 75;
With symptoms of IBS with predominant diarrhea according to the Rome III criteria;
For women of childbearing age: effective contraception and agreement to keep it throughout the study;
General and mental health compatible with participation in the study and to be followed as an outpatient in the opinion of the investigator: no clinically significant and relevant abnormality according to medical history and physical examination;
Agreeing to maintain their lifestyle during the study (same eating habits and physical activity);
Able and willing to participate in research in accordance with the protocol procedures particularly regarding consumption of the product under consideration and having signed an informed consent form dated;
Belonging to a social security scheme;
Willing to be included in the file of volunteers participating in biomedical research.
Exclusion Criteria:
Having a history of hypersensitivity to any of the ingredients of the product under consideration;
Having a history of hypersensitivity to fluorescein and / or red carmine (E120 food coloring);
With immunodeficiency or with a severe or progressive disease (cardiac, pulmonary, hepatic, renal, hematologic, neoplastic, or infectious);
With acute or severe chronic disease (chronic alcoholism, drug addiction) found incompatible with participation in the study by the investigator;
Suffering from a metabolic disorder or a chronic inflammatory digestive disease affecting the intestinal transit or absorption of nutrients such as diabetes, hyperthyroidism, celiac disease or Crohn's disease;
Having a medical history or current condition that, according to the investigator, may interfere with the results of the study or expose the subject to additional risk;
Currently under medication or food supplement treatment, according to the investigator, may interfere with the results of the study or stopped within too short before inclusion in V1 (less than a month for antibiotics, pre and probiotics, less than 14 days for antidiarrheal, steroidal anti-inflammatories, NSAIDs, aspirin, antihistamines and drugs. treatment with maximum 2 concomitant psychotropic can be tolerated only if it exists for more than 3 months before inclusion);
Having a lifestyle incompatible with the study by the investigator;
Woman during pregnancy or breastfeeding or planning to become pregnant within 2 months;
Planning to travel and hold during the study period or impossible to contact in case of emergency;
Having a psychological or linguistic inability to understand and sign the informed consent;
Participating in another clinical trial or exclusion period of a previous clinical trial;
Having received over the past 12 months, no more than 4,500 euros in payment for participation in clinical trials;
Under legal protection (guardianship, trusteeship) or deprived of his rights under the administrative or judicial decision.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Coron Emmanuel, Pr.
Organizational Affiliation
Nantes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU-Hôtel-Dieu, Service d'Hépato-gastro-entérologie
City
Nantes
ZIP/Postal Code
44093
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
We'll reach out to this number within 24 hrs